TxCell SA has announced that Dr. Miguel Forte, chief operating officer, and Dr. Arnaud Foussat, chief scientific officer of TxCell, will present at three forthcoming leading cell and gene therapy and ophthalmology conferences. These three conferences are the International Society of Cellular Therapy Europe 2015 Regional Meeting, the Phacilitate Cell & Gene Therapy Europe conference and the European Association for Vision and Eye Research EVER 2015 Congress.
Both Dr. Forte and Dr. Foussat, in addition to Christelle Boniface, Regulatory Affairs Manager, TxCell, will present at the International Society of Cellular Therapy (ISCT) Europe 2015 Regional Meeting, September 24-26 2015, Barceló Sevilla Renacimiento Hotel, Seville, Spain. The purpose of ISCT Europe is to drive the translation of cellular therapies for the benefit of patients. Specifically, the meeting will focus on challenges and critical success factors for the development of cellular therapies. Dr. Miguel Forte will also chair meetings of the ISCT Commercialization Committee at the conference.
At the meeting, Dr. Forte will chair the ISCT lead workshop session entitled ‘Clinical to Commercial Translation of Cellular Therapies for the Benefit of Patients’. In the workshop, he will also deliver a presentation entitled ‘What companies need to do to navigate the translation process’. This will be on September 24, 14.15 - 15.45 at Room Seville 1. Dr. Foussat will be a speaker in the Plenary Session 2 – ‘New Frontiers in the Treatment of Ophthalmological Disorders with Cell-Based Therapies’, September 25, 8.00 - 9.30, Room Seville 1-2.
He will deliver a presentation entitled ‘Autologous Treg cell therapy for non-infectious uveitis’. Christelle Boniface, Regulatory Affairs Manager, TxCell will present at the technical session 3 - ‘Patient materials to be used for the pharmaceutical development of autologous ATMPs - ethical and other implications’, September 25, 12.30 – 13.30. Her presentation is entitled ‘Materials from both patients and healthy donors are required to validate manufacturing process of autologous cell therapies in inflammatory diseases: challenges and regulatory pathway’.
Dr. Forte will also speak at the Phacilitate Cell & Gene Therapy Europe conference, September 29 – 30, Barcelona, Spain. He will participate in the roundtable on ‘What’s the future for Hospital Exemption in the EU?’ on September 30, 12.00 to 12.30 and deliver a presentation on clinical trials with ATMP (Advanced-Therapy Medicinal Products) in Europe, September 30, 15.00 to 15.50.
Lastly, Dr. Foussat will present at the European Association for Vision and Eye Research EVER 2015 Congress, Nice, France, October 7-10, 2015. The presentation will be entitled ‘Treg-based immunotherapy of non-infectious uveitis (NIU)’ and is scheduled in the ‘Mechanisms in inflammatory disease to outcomes of novel therapies’ session, part 1, Thursday, October 8, 2015 at 16.00, presentation number 2571.
“TxCell is contributing to a growing body of scientific evidence establishing a critical role for T regulatory cells in autoimmunity and chronic inflammation. This is illustrated by the level of attention TxCell programs have been getting at global conferences this year,” said Stéphane Boissel, CEO of TxCell. “In addition, updating the market about our most recent technological developments presents an opportunity to discuss potential business partnerships with key players in the field.”